Elutia Inc. (ELUT)
NASDAQ: ELUT · Real-Time Price · USD
0.9757
-0.0343 (-3.40%)
At close: May 5, 2026, 4:00 PM EDT
0.9800
+0.0043 (0.44%)
After-hours: May 5, 2026, 6:10 PM EDT
Elutia Revenue
In the year 2025, Elutia had annual revenue of $12.29M, down -15.03%. Elutia had revenue of $3.27M in the quarter ending December 31, 2025, with 16.16% growth.
Revenue (ttm)
$18.89M
Revenue Growth
-2.96%
P/S Ratio
3.67
Revenue / Employee
$472,808
Employees
26
Market Cap
43.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.29M | -2.17M | -15.03% |
| Dec 31, 2024 | 14.47M | -10.28M | -41.54% |
| Dec 31, 2023 | 24.75M | 896.00K | 3.76% |
| Dec 31, 2022 | 23.85M | -23.54M | -49.68% |
| Dec 31, 2021 | 47.39M | 4.71M | 11.03% |
| Dec 31, 2020 | 42.68M | -219.00K | -0.51% |
| Dec 31, 2019 | 42.90M | 3.86M | 9.90% |
| Dec 31, 2018 | 39.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 436.97M |
| Nortech Systems | 118.37M |
| Pulmonx | 88.55M |
| TELA Bio | 80.28M |
| Cytosorbents | 37.06M |
| electroCore | 32.03M |
| Baird Medical Investment Holdings | 22.54M |
| NeuroOne Medical Technologies | 11.72M |
ELUT News
- 5 days ago - Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - GlobeNewsWire
- 6 weeks ago - Elutia Transcript: Sidoti March Small-Cap Virtual Conference - Transcripts
- 7 weeks ago - Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19 - GlobeNewsWire
- 7 weeks ago - Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Elutia Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process - GlobeNewsWire
- 2 months ago - Elutia Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market - GlobeNewsWire